Alpelisib 50 mg, 150 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50 mg, 150 mg, 200 mg

Reference Brands: Piqray (USA/EU)

Category: Oncology Cancer Care

Alpelisib is a Oncology Cancer Care product available as Tablets in strengths 50 mg, 150 mg, 200 mg. It corresponds to the reference brand Piqray (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Alpelisib, also known by its brand name Piqray, is a targeted kinase inhibitor used in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is indicated for use in postmenopausal women and men whose tumors carry a mutation in the PIK3CA gene and whose disease has progressed during or after prior hormone therapy.

Alpelisib works by selectively inhibiting the phosphatidylinositol-3-kinase (PI3K) alpha pathway, which plays a key role in cancer cell growth, survival, and metabolism. By blocking this pathway, alpelisib helps slow tumor progression and may induce cancer cell death. Its targeted mechanism allows for a more personalized treatment approach in patients with genetically driven breast cancer.

In addition to its approved use in breast cancer, alpelisib is being actively studied for its potential role in treating other types of cancer associated with PI3K pathway alterations. Available as an oral tablet, Piqray represents an important advancement in precision oncology, offering an effective treatment option for patients with limited response to standard hormone therapies.